On this page
What each program costs in New York
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the Empire Plan (NYSHIP) cover GLP-1s for weight loss?
The Empire Plan's January 2026 Advanced Flexible Formulary lists Wegovy and Zepbound as preferred anti-obesity agents, each requiring prior authorization.
NYS Department of Civil Service
The 2026 preferred drug list, administered by CVS Caremark, groups Wegovy and Zepbound under anti-obesity agents and marks each PA (prior authorization).
“ANTI-OBESITY AGENTS liraglutide PA CONTRAVE PA WEGOVY PA ZEPBOUND PA”
https://www.cs.ny.gov/employee-benefits/shared/drug-lists/2026/aff-preferred-jan-2026.pdf · read Oct 29, 2026
NYS Department of Civil Service
The list describes itself as covered drugs by therapeutic class.
“This list includes commonly prescribed covered drugs by therapeutic class, a list of commonly prescribed covered drugs in alphabetic order (Quick Reference Drug List), a list of commonly prescribed non-preferred (Level 3) drugs along with covered preferred drug alternatives, and a list of excluded drugs along with covered preferred drug alternatives.”
https://www.cs.ny.gov/employee-benefits/shared/drug-lists/2026/aff-preferred-jan-2026.pdf · read Oct 29, 2026
Does New York Medicaid cover GLP-1s for weight loss?
Not covered for weight loss
NYRx excludes Ozempic, Wegovy and Mounjaro for weight loss and says drugs indicated for weight loss such as Zepbound are not covered; its drug list allows Wegovy for heart disease and Zepbound for sleep apnea. Read from state documents Nov 6, 2026.
What New York Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. New York State Department of Health.
WegovyNo
Drug list row: cardiovascular disease with BMI of 40 or higher, lifestyle changes, two treatment attempts per lifetime.
“GLP-1 agonists, including but not limited to Ozempic, Wegovy, and Mounjaro are excluded from coverage for weight loss indications.”
New York State Department of Health, NYRx · No effective date on the document · read Nov 6, 2026
“Weight loss is not and never has been a Medicaid-covered indication.”
New York State Department of Health, NYRx · No effective date on the document · read Nov 6, 2026
“Confirm diagnosis of cardiovascular disease”
New York State Department of Health, NYRx · No effective date on the document · read Nov 6, 2026
ZepboundNo
Drug list row: obstructive sleep apnea with BMI of 40 or higher, lifestyle changes, two treatment attempts per lifetime.
“Eli Lilly and Company Drugs indicated for weight loss are not covered pursuant to SSA §1927(d)(2)”
New York State Department of Health, NYRx · No effective date on the document · read Nov 6, 2026
“Weight loss is not and never has been a Medicaid-covered indication.”
New York State Department of Health, NYRx · No effective date on the document · read Nov 6, 2026
“Confirm diagnosis of obstructive sleep apnea (OSA)”
New York State Department of Health, NYRx · No effective date on the document · read Nov 6, 2026
OzempicNo
Listed in the NYRx GLP-1 type 2 diabetes class; clinical criteria must confirm a Medicaid-covered indication.
“GLP-1 agonists, including but not limited to Ozempic, Wegovy, and Mounjaro are excluded from coverage for weight loss indications.”
New York State Department of Health, NYRx · No effective date on the document · read Nov 6, 2026
MounjaroNo
Listed in the NYRx GLP-1 type 2 diabetes class; clinical criteria must confirm a Medicaid-covered indication.
“GLP-1 agonists, including but not limited to Ozempic, Wegovy, and Mounjaro are excluded from coverage for weight loss indications.”
New York State Department of Health, NYRx · No effective date on the document · read Nov 6, 2026
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from New York State Department of Health documents. KFF's January 2026 map listed this program as not covered; the documents we read agree.
Weight loss
Not covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
208 prescriptions
Ozempic and Mounjaro, 2025
683,235 prescriptions
Neighbours covering weight loss
0 of 5
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your New York Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed New York Medicaid as "not covered" for GLP-1s for obesity under fee-for-service.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether New York Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does New York Medicaid pay for?
815,882 GLP-1 prescriptions in 2025, 3rd of the 50 states and DC, with $929.5 million reimbursed before rebates. Counting the share other payers covered, $940.4 million.
Prescriptions, 2025
815,882
3rd of 51
Medicaid paid
$929.5M
3rd of 51, before rebates
Per prescription
$1,139
$1,051 nationally
Weight-loss brands
0.0%
49th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. New York is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 0.0% of New York Medicaid's GLP-1 prescriptions in 2025 (208). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Ozempic was New York Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Ozempic | 464,371 | 57% | $541.1 million | $1,165 |
| Mounjaro | 218,864 | 27% | $232.3 million | $1,062 |
| Trulicity | 103,672 | 13% | $120.5 million | $1,162 |
| Rybelsus | 24,252 | 3.0% | $32.6 million | $1,345 |
| Liraglutide (generic) | 3,391 | 0.4% | $1.9 million | $562 |
| Victoza | 816 | 0.1% | $633,976 | $777 |
| Bydureon | 308 | 0.0% | $277,839 | $902 |
| Wegovyapproved for weight management | 197 | 0.0% | $214,617 | $1,089 |
| Zepboundapproved for weight management | 11 | 0.0% | $1,041 | $95 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
Which FDA-registered outsourcing facilities are in New York?
FDA's register of 503B outsourcing facilities, updated Nov 17, 2026, lists 2 in New York. The register does not say which, if any, supplies a program on this page.
- Galaxy Pharmaceuticals, LLC, Albany. Registered since Jan 26, 2024; not yet inspected by FDA.
- Pine Pharmaceuticals, LLC, Tonawanda. Registered since Mar 9, 2018; last FDA inspection Nov 14, 2025.
On Medicare in New York?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
New York and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
None of the 5 states next to New York covers GLP-1s for weight loss through Medicaid. None has a lower cash floor than New York's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| New York | Not covered | 19 | $39/mo |
| Connecticut | Not covered | 19 | $39/moWellmedr |
| Massachusetts | Not covered | 18 | $39/moWellmedr |
| New Jersey | Not covered | 19 | $39/moWellmedr |
| Pennsylvania | Not covered | 19 | $39/moWellmedr |
| Vermont | Not covered | 19 | $39/moWellmedr |






















